JP2009526834A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009526834A5 JP2009526834A5 JP2008554886A JP2008554886A JP2009526834A5 JP 2009526834 A5 JP2009526834 A5 JP 2009526834A5 JP 2008554886 A JP2008554886 A JP 2008554886A JP 2008554886 A JP2008554886 A JP 2008554886A JP 2009526834 A5 JP2009526834 A5 JP 2009526834A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- compound
- alkyl
- formula
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 230000003941 amyloidogenesis Effects 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 7
- 125000002252 acyl group Chemical group 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 238000009825 accumulation Methods 0.000 claims 5
- 230000007082 Aβ accumulation Effects 0.000 claims 4
- -1 C 1 -C 6 alkyl Chemical group 0.000 claims 4
- 238000004220 aggregation Methods 0.000 claims 4
- CDAISMWEOUEBRE-UHFFFAOYSA-N inositol Chemical compound OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims 4
- 230000004845 protein aggregation Effects 0.000 claims 4
- 230000012846 protein folding Effects 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 230000002159 abnormal effect Effects 0.000 claims 3
- 230000002688 persistence Effects 0.000 claims 3
- 230000004083 survival effect Effects 0.000 claims 3
- 208000031124 Dementia Alzheimer type Diseases 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 230000009286 beneficial effect Effects 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 230000035508 accumulation Effects 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 230000009089 cytolysis Effects 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000008021 deposition Effects 0.000 claims 1
- 230000037213 diet Effects 0.000 claims 1
- 235000005911 diet Nutrition 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- CDAISMWEOUEBRE-NIPYSYMMSA-N epi-inositol Chemical class O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](O)[C@H]1O CDAISMWEOUEBRE-NIPYSYMMSA-N 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 230000002045 lasting effect Effects 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77481806P | 2006-02-17 | 2006-02-17 | |
| PCT/IB2007/001929 WO2007129221A2 (en) | 2006-02-17 | 2007-02-16 | Compositions comprising an epi-inositol compounds and methods for treatment of disorders of protein aggregation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009526834A JP2009526834A (ja) | 2009-07-23 |
| JP2009526834A5 true JP2009526834A5 (https=) | 2010-03-25 |
Family
ID=38668147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008554886A Withdrawn JP2009526834A (ja) | 2006-02-17 | 2007-02-16 | タンパク質凝集の疾患の治療のための組成物および方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20070197453A1 (https=) |
| EP (1) | EP1993523A4 (https=) |
| JP (1) | JP2009526834A (https=) |
| CA (1) | CA2642647A1 (https=) |
| WO (1) | WO2007129221A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7521481B2 (en) * | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| US7985847B2 (en) | 2006-05-08 | 2011-07-26 | Biojoule Ltd. | Recovery of lignin and water soluble sugars from plant materials |
| AU2008293139A1 (en) | 2007-08-31 | 2009-03-05 | Vertichem Corporation | Lignin and other products isolated from plant material, and methods and compositions therefor |
| AT506535B1 (de) | 2008-02-22 | 2010-04-15 | Affiris Forschungs & Entwicklungs Gmbh | Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden |
| US9116157B2 (en) | 2010-11-05 | 2015-08-25 | Brandeis University | Ice-cleaved alpha-synuclein as a biomarker |
| JP6576400B2 (ja) * | 2017-07-27 | 2019-09-18 | アンリツ株式会社 | 移動端末試験装置とそのパラメータ変更方法 |
| AU2020341464A1 (en) * | 2019-09-05 | 2022-04-21 | Trevena, Inc. | Methods of treating epilepsy using the same |
| EP4694889A1 (en) * | 2023-04-13 | 2026-02-18 | Acelot, Inc. | Compounds and methods for treating protein aggregation diseases |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4454151A (en) * | 1982-03-22 | 1984-06-12 | Syntex (U.S.A.) Inc. | Use of pyrrolo pyrroles in treatment of ophthalmic diseases |
| US4474806A (en) * | 1982-05-10 | 1984-10-02 | Merck & Co., Inc. | Sulfonyl or carbonyl inositol derivatives useful as anti-inflammatory/analgesic agents |
| KR0185215B1 (ko) * | 1990-11-30 | 1999-05-01 | 요시다 쇼오지 | 서방성 안구삽입용 약제 |
| US5756541A (en) * | 1996-03-11 | 1998-05-26 | Qlt Phototherapeutics Inc | Vision through photodynamic therapy of the eye |
| US6818430B1 (en) * | 1999-06-07 | 2004-11-16 | Hokko Chemical Industry Co., Ltd. | Process for producing L-epi-2-inosose and novel process for producing epi-inositol |
| US6331313B1 (en) * | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
| WO2002062385A2 (en) * | 2001-02-06 | 2002-08-15 | Qlt, Inc. | Method to prevent vision loss |
| US8034803B2 (en) * | 2001-02-06 | 2011-10-11 | Qlt Inc. | Photodynamic therapy of occult age-related macular degeneration |
| US20030181531A1 (en) * | 2003-02-11 | 2003-09-25 | David Sherris | Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases |
| US6599891B2 (en) * | 2001-07-20 | 2003-07-29 | Qlt Inc. | Treatment of macular edema |
| US20040058313A1 (en) * | 2002-04-24 | 2004-03-25 | Abreu Marcio Marc | Compositions, targets, methods and devices for the therapy of ocular and periocular disorders |
| US7521481B2 (en) * | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| ATE458042T1 (de) * | 2003-10-14 | 2010-03-15 | Hokko Chem Ind Co | Verfahren zur herstellung von scyllo-inositol |
| US8193250B2 (en) * | 2004-10-22 | 2012-06-05 | Mount Sinai School Of Medicine | Compositions and methods for treating alzheimer's disease and related disorders and promoting a healthy nervous system |
| CN103301094A (zh) * | 2004-11-17 | 2013-09-18 | 乔安妮·麦克劳林 | 用于治疗蛋白聚集疾病的含鲨肌醇衍生物的组合物和方法 |
-
2007
- 2007-02-16 EP EP07789484A patent/EP1993523A4/en not_active Withdrawn
- 2007-02-16 US US11/707,156 patent/US20070197453A1/en not_active Abandoned
- 2007-02-16 CA CA002642647A patent/CA2642647A1/en not_active Abandoned
- 2007-02-16 JP JP2008554886A patent/JP2009526834A/ja not_active Withdrawn
- 2007-02-16 WO PCT/IB2007/001929 patent/WO2007129221A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009526834A5 (https=) | ||
| CN103561770B (zh) | 硫辛酰基化合物及其用于治疗缺血性伤害的用途 | |
| JP2008520589A5 (https=) | ||
| JP2018035197A5 (https=) | ||
| WO2019020070A1 (zh) | 哌嗪并杂芳基类衍生物、其制备方法及其在医药上的应用 | |
| TW201840544A (zh) | 雙環雜芳基衍生物及其製備與用途 | |
| JP2015510941A5 (https=) | ||
| WO2011052888A3 (ko) | (3-플루오로-2-히드록시)프로필 작용기가 도입된 아릴 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물 | |
| WO2014138437A1 (en) | Steroid conjugates | |
| CN112851648B (zh) | 布雷菲德菌素a酯类衍生物在抗肿瘤药物中的应用 | |
| JP2018138594A (ja) | オナプリストン多形体及び使用方法 | |
| JP2011512370A (ja) | ベンゾフェナントリジン構造を有する抗腫瘍薬およびそれらを含有する製剤 | |
| JP2020100623A (ja) | 炎症及び疼痛の治療のための組成物及び方法 | |
| CN118076582A (zh) | 降低免疫不耐受和治疗自身免疫病症的组合物和方法 | |
| JP2016537432A5 (https=) | ||
| TW201139421A (en) | Novel ep4 agonist | |
| US11219633B2 (en) | Nucleobase analogue derivatives and their applications | |
| ES2671730T3 (es) | Terapia de combinación para el cáncer de ovario | |
| MX2009009113A (es) | Nuevos indoles 2-heteroaril sustituidos 695. | |
| JP4232866B2 (ja) | 細胞障害抑制剤 | |
| JP2008535907A5 (https=) | ||
| EP3641756A1 (en) | Tricyclic compounds as cyp1 inhibitors | |
| JP5830983B2 (ja) | 抗癌剤の副作用軽減剤 | |
| JP4490536B2 (ja) | 脳血管障害に基づく疾患の予防又は治療薬 | |
| RU2799446C2 (ru) | Ингибиторы протеин-тирозинфосфатазы и способы их применения |